Evidence map›Paper›PMID 40459653›Full record

ReviewCurrent allergy and asthma reports2025

AI-Driven Biomarker Discovery and Personalized Allergy Treatment: Utilizing Machine Learning and NGS.

Mahbod Fazlali, Maedeh Nasira, Ali Moravej

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current allergy and asthma reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mahbod Fazlali *Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.ORCID http://orcid.org/0009-0003-2743-0748
Maedeh Nasira *Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.ORCID http://orcid.org/0009-0000-5701-9368
Ali MoravejNoncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran. Amoravej@gmail.com.ORCID http://orcid.org/0000-0002-5791-5012

Funding

Fasa University of Medical Sciences 403153
6 · The paper itself

Abstract

PURPOSE OF REVIEW: This review explores the transformative potential of artificial intelligence (AI) and next-generation sequencing (NGS) in allergy diagnostics and treatment. It focuses on leveraging these technologies to enhance precision in biomarker discovery, patient stratification, and personalized management strategies for allergic diseases. RECENT

findingsAI-driven algorithms, particularly machine learning and deep learning, have enabled the identification of complex molecular patterns and predictive markers in allergies, such as IgE levels and cytokine profiles. Integration with NGS techniques, including single-cell RNA sequencing, has uncovered unique immune response signatures, providing insights into molecular mechanisms driving allergic reactions. These innovations have advanced diagnostic accuracy, treatment personalization, and real-time monitoring capabilities, especially in allergen immunotherapy. Combining AI and NGS technologies represents a paradigm shift in allergy research and clinical practice. These advancements facilitate precision diagnostics and personalized treatments, ensuring safer and more effective interventions tailored to individual patient profiles. Despite data integration and clinical implementation challenges, these technologies promise improved outcomes and quality of life for allergy sufferers.

Indexed as

Artificial IntelligenceHigh-Throughput Nucleotide SequencingHypersensitivityMachine LearningPrecision MedicineBiomarkersHumansBiomarkersAllergy diagnosticsBiomarker discoveryMachine learningNext-generation sequencingPersonalized treatment

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.